Chest Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blair, G. P.
Right arrow Articles by Light, R. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blair, G. P.
Right arrow Articles by Light, R. W.

Chest, Vol 86, 524-528, Copyright © 1984 by American College of Chest Physicians

ARTICLES

Treatment of chronic obstructive pulmonary disease with corticosteroids. Comparison of daily vs alternate-day therapy

GP Blair and RW Light

We compared the efficacy of corticosteroid therapy initiated as an alternate-day regimen to that of a four-times-daily regimen in patients with stable chronic obstructive pulmonary disease. In this double-blind study, 44 patients with moderate to severe COPD (mean FEV1 740 +/- 310 ml) were hospitalized and randomly allocated to receive methylprednisolone, 8 mg qid, 64 mg qod, or placebo for a ten-day period. The mean FEV1 and FVC improved significantly to a comparable degree in both steroid-treated groups, but not in the placebo-treated group. Eight of the 29 steroid-treated patients (28 percent) had improved FEV1 of more than 25 percent compared with only one of the 15 placebo-treated patients. Those in the qod group also had notable improvement in SaO2. Although the correlation between the improvement after the administration of nebulized bronchodilators and that after corticosteroid therapy was significant, some patients had more than a 25 percent improvement in their FEV1 with corticosteroids, but less than a 10 percent improvement after nebulized bronchodilators. We conclude that a substantial proportion of all patients with stable COPD will have a greater than 25 percent improvement in their flow rates with corticosteroid administration. Since the response to a qod regimen is comparable to that of a qid regimen, and since the qod regimen is associated with fewer side effects, we recommend that a qod regimen be tried initially.


This article has been cited by other articles:


Home page
 ChestHome page
S. Nava and M. L. Compagnoni
Controlled Short-term Trial of Fluticasone Propionate in Ventilator-Dependent Patients With COPD
Chest, October 1, 2000; 118(4): 990 - 999.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
K. L. RICE, J. B. RUBINS, F. LEBAHN, C. M. PARENTI, P. G. DUANE, M. KUSKOWSKI, A. M. JOSEPH, and D. E. NIEWOEHNER
Withdrawal of Chronic Systemic Corticosteroids in Patients with COPD . A Randomized Trial
Am. J. Respir. Crit. Care Med., July 1, 2000; 162(1): 174 - 178.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
D. E. NIEWOEHNER, D. COLLINS, and M. L.E. f. t. D. o.  Veterans Affairs Cooperative Study
Relation of FEV1 to Clinical Outcomes during Exacerbations of Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med., April 1, 2000; 161(4): 1201 - 1205.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1984 by the American College of Chest Physicians.